TMB-High is an inclusion criterion in 25 clinical trials for malignant solid tumor, of which 23 are open and 2 are closed. Of the trials that contain TMB-High and malignant solid tumor as inclusion criteria, 8 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), and 14 are phase 2 (13 open) [5].

Pembrolizumab has evidence of efficacy in patients with TMB-High in malignant solid tumor [5].

TMB-High is an inclusion criterion in 11 clinical trials for non-small cell lung carcinoma, of which 10 are open and 1 is closed. Of the trials that contain TMB-High and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 4 (1 open) [5].

TMB-High is an inclusion criterion in 7 clinical trials for colorectal carcinoma, of which 6 are open and 1 is closed. Of the trials that contain TMB-High and colorectal carcinoma as inclusion criteria, 4 are phase 1 (4 open) and 3 are phase 2 (2 open) [5].

TMB-High is an inclusion criterion in 7 clinical trials for endometrial carcinoma, of which 6 are open and 1 is closed. Of the trials that contain TMB-High and endometrial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].

TMB-High is an inclusion criterion in 7 clinical trials for melanoma, of which 7 are open and 0 are closed. Of the trials that contain TMB-High and melanoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [5].

TMB-High is an inclusion criterion in 6 clinical trials for cervical carcinoma, of which 6 are open and 0 are closed. Of the trials that contain TMB-High and cervical carcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 5 are open and 0 are closed. Of the trials that contain TMB-High and breast carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [5].

TMB-High is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 4 are open and 0 are closed. Of the trials that contain TMB-High and gastric carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

TMB-High is an inclusion criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain TMB-High and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

TMB-High is an inclusion criterion in 4 clinical trials for small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain TMB-High and small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain TMB-High and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain TMB-High and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 3 clinical trials for glioma, of which 2 are open and 1 is closed. Of the trials that contain TMB-High and glioma as inclusion criteria, 2 are phase 2 (1 open) and 1 is no phase specified (1 open) [5].

TMB-High is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain TMB-High and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 3 are open and 0 are closed. Of the trials that contain TMB-High and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain TMB-High and urothelial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for cervical squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for esophageal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and glioblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for Merkel cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and Merkel cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for skin squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and skin squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 2 clinical trials for vulvar squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TMB-High and vulvar squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for alveolar rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and alveolar rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for anal canal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and anal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for appendix neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and appendix neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and carcinoma of unknown primary as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for childhood central nervous system embryonal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and childhood central nervous system embryonal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for colon neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and colon neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and endometrial adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for endometrial undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and endometrial undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for Ewing sarcoma/peripheral primitive neuroectodermal tumor of bone, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and Ewing sarcoma/peripheral primitive neuroectodermal tumor of bone as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and fallopian tube carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for gallbladder adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and gallbladder adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for high-grade endometrial stromal sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and high-grade endometrial stromal sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for lung neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and lung neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for ovarian clear cell tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and ovarian clear cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and pancreatic neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for rectal neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and rectal neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and salivary gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for small intestinal neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and small intestinal neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and synovial sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for undifferentiated (embryonal) sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and undifferentiated (embryonal) sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for vaginal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and vaginal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TMB-High is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains TMB-High and Wilms tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].